```
=> File .Biotech
=> s (sulfite# or sulphite#)
L1      141102 (SULFITE# OR SULPHITE#)

=> s l1 and (sodium sulfite or sodium sulphite or Na2SO3 or sulfur dioxide or
sulphur dioxide or SO2)
L2       51851 L1 AND (SODIUM SULFITE OR SODIUM SULPHITE OR NA2SO3 OR SULFUR
               DIOXIDE OR SULPHUR DIOXIDE OR SO2)

=> s l2 and (protein(l)soy or whey)
L3         421 L2 AND (PROTEIN(L) SOY OR WHEY)

=> s l3 and (prepar? or modif? or mak? or isolat? or formulat? or produc?)
   6 FILES SEARCHED...
L4         408 L3 AND (PREPAR? OR MODIF? OR MAK? OR ISOLAT? OR FORMULAT? OR
               PRODUC?)

=> s l4 and (ppt# or precip? or aggregat? or concentrat? or centrifug?)
L5         368 L4 AND (PPT# OR PRECIP? OR AGGREGAT? OR CONCENTRAT? OR CENTRIFU
               G?)

=> s l5 and (sulfonat?(w)protein or protein(l)sulfon?)
   6 FILES SEARCHED...
L6         142 L5 AND (SULFONAT?(W) PROTEIN OR PROTEIN(L) SULFON?)

=> s l6 and (acid?(w)pH)
L7          21 L6 AND (ACID?(W) PH)

=> s l6 and (enzymat?(w)hydrolysis)
L8          12 L6 AND (ENZYMAT?(W) HYDROLYSIS)

=> s l7 and l8
L9           4 L7 AND L8

=> d l9 1-4 bib ab

L9   ANSWER 1 OF 4  USPATFULL on STN
AN     2003:319282  USPATFULL
TI     Administration of acetylcholinesterase inhibitors to the cerebral spinal
       fluid
IN     Quay, Steven C., Edmonds, WA, UNITED STATES
PI     US 2003225031      A1   20031204
AI     US 2003-439108     A1   20030515 (10)
PRAI   US 2002-382122P     20020521 (60)
DT     Utility
FS     APPLICATION
LREP   Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell,
       WA, 98021-8906
CLMN   Number of Claims: 62
ECL    Exemplary Claim: 1
DRWN   1 Drawing Page(s)
LN.CNT 2144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Methods and compositions are disclosed that provide acetylcholinesterase
       inhibitors for the prevention and treatment of diseases and disorders of
       the central nervous system, including dementia such as Alzheimer's
       disease, to the central nervous system via intranasal delivery. The
       methods and compositions of the present invention provide therapeutic
       concentrations of the acetylcholinesterase inhibitor in the
       cerebrospinal fluid of a mammal without the attendant disadvantages,
       risks and side effects of oral or injection delivery.

L9   ANSWER 2 OF 4  USPATFULL on STN
AN     2003:120747  USPATFULL
TI     Blood cell deficiency treatment method
```

IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L9 ANSWER 3 OF 4 USPATFULL on STN
AN 2003:86817 USPATFULL
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND

Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3 β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid **formulation** comprising less than about 3% v/v water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L9 ANSWER 4 OF 4 USPATFULL on STN
AN 2001:59446 USPATFULL
TI Short-chained peptide material
IN Cho, Myong J., Chesterfield, MO, United States
Singer, David A., St. Louis, MO, United States
Lin, Santa H., late of St. Louis, MO, United States deceased, Terry T. Lin, executor
PA Protein Technologies Int'l Inc., St. Louis, MO, United States (U.S. corporation)
PI US 6221423 B1 20010424
AI US 1998-59655 19980413 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Weier, Anthony J.

LREP Taylor, Richard B.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A short chain peptide material is provided containing a peptide material derived from a protein material. At least a majority of the peptides in the peptide material have a peptide chain length of 7 peptides or less. The peptide material is at least 95% soluble in an aqueous solution having a pH at which the protein material from which the peptide material is derived is insoluble. A process for forming the short chain peptide material is also provided. A slurry is formed of a protein material at a pH at which the protein material is substantially insoluble. The protein material is contacted with an enzyme having substantial endopeptidase activity and substantial exopeptidase activity at a temperature and for a time sufficient to form the peptide material of the invention.

=> d his

(FILE 'HOME' ENTERED AT 11:49:47 ON 26 MAY 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
ENTERED AT 11:50:33 ON 26 MAY 2004
L1 141102 S (SULFITE# OR SULPHITE#)
L2 51851 S L1 AND (SODIUM SULFITE OR SODIUM SULPHITE OR NA2SO3 OR SULFUR
L3 421 S L2 AND (PROTEIN(L)SOY OR WHEY)
L4 408 S L3 AND (PREPAR? OR MODIF? OR MAK? OR ISOLAT? OR FORMULAT? OR
L5 368 S L4 AND (PPT# OR PRECIP? OR AGGREGAT? OR CONCENTRAT? OR CENTR
L6 142 S L5 AND (SULFONAT?(W)PROTEIN OR PROTEIN(L)SULFON?)
L7 21 S L6 AND (ACID?(W)PH)
L8 12 S L6 AND (ENZYMAT?(W)HYDROLYSIS)
L9 4 S L7 AND L8

=> s l8 and (pepsin or trypsin)
L10 7 L8 AND (PEPSIN OR TRYPSIN)

=> d l10 1-7 bib ab

L10 ANSWER 1 OF 7 USPATFULL on STN
AN 2004:127423 USPATFULL
TI Pharmaceutical compositions and treatment methods - 4
IN Ahlem, Clarence Nathaniel, San Diego, CA, UNITED STATES
Frincke, James Martin, San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell Neil, Oak Hills, CA, UNITED STATES
PI US 2004097406 A1 20040520
AI US 2003-607035 A1 20030625 (10)
RLI Division of Ser. No. US 2000-535675, filed on 23 Mar 2000, GRANTED, Pat. No. US 6667299 Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 2000-190140P 20000316 (60)
US 1999-164048P 19991108 (60)
US 1999-140028P 19990616 (60)
US 1999-126056P 19991019 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121

CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 9339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L10 ANSWER 2 OF 7 USPATFULL on STN
AN 2004:57966 USPATFULL
TI Pharmaceutical compositions and treatment methods
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Heggie, William, Cabanas, PORTUGAL
Carvalho, Luis D., Paio Pires, PORTUGAL
PI US 2004043973 A1 20040304
AI US 2002-319356 A1 20021213 (10)
RLI Continuation of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING
PRAI US 2000-190140P 20000316 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 9007
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L10 ANSWER 3 OF 7 USPATFULL on STN
AN 2003:332378 USPATFULL
TI Pharmaceutical compositions and treatment methods
IN Ahlem, Clarence Nathaniel, San Diego, CA, United States
de Carvalho, Luis Daniel dos Anjos, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
PA Hollis-Eden Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6667299 B1 20031223
AI US 2000-535675 20000323 (9)
PRAI US 2000-190140P 20000316 (60)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Badio, Barbara P.
LREP Muenchau, Daryl D.
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 8994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising, 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L10 ANSWER 4 OF 7 USPATFULL on STN
AN 2003:319282 USPATFULL
TI Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2003225031 A1 20031204
AI US 2003-439108 A1 20030515 (10)
PRAI US 2002-382122P 20020521 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compositions of the present invention provide therapeutic **concentrations** of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

L10 ANSWER 5 OF 7 USPATFULL on STN
AN 2003:120747 USPATFULL
TI Blood cell deficiency treatment method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US

1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED

PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)

DT Utility

FS APPLICATION

LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 19428

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L10 ANSWER 6 OF 7 USPATFULL on STN

AN 2003:99213 USPATFULL

TI High capacity methods for separation, purification, **concentration**, immobilization and synthesis of compounds and applications based thereupon

IN Lee, William, Cambridge, MA, UNITED STATES
Saito, Kyoichi, Tokyo, JAPAN

PI US 2003068317 A1 20030410

AI US 2002-126297 A1 20020419 (10)

PRAI US 2001-285146P 20010420 (60)
US 2001-339951P 20011210 (60)
US 2001-339949P 20011210 (60)
US 2002-347547P 20020111 (60)

DT Utility

FS APPLICATION

LREP MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY AND POPEO, P.C., One Financial Center, Boston, MA, 02111

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 34 Drawing Page(s)

LN.CNT 2906

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions are provided herein comprising a base material having

engrafted polymer brushes. The polymer brushes further comprise one or more functional groups immobilized along the surface of the brushes in a plurality of layers, which confer functional properties to the base material compositions. Methods of using these compositions include deoxygenation of a sample solution, hydrolysis of denaturing agents in a sample solution, resolution of racemic mixtures in a sample solution, and purification, and **concentration** of target compounds.

L10 ANSWER 7 OF 7 USPATFULL on STN
AN 2003:86817 USPATFULL
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-110127P 19981127 (60)
US 1999-161453P 19991025 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1998-112206P 19981215 (60)
US 2000-257071P 20001220 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3 β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid **formulation** comprising less than about 3% v/v water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to **make** and use these immunomodulatory

compositions and **formulations.**

```
=> s l6 and (without(l)oxidizing agent or no oxidiz?(w)agent#)
L11         28 L6 AND (WITHOUT(L) OXIDIZING AGENT OR NO OXIDIZ?(W) AGENT#)

=> s Savolainen, J?/au
L12        414 SAVOLAINEN, J?/AU

=> s l11 and l12
L13          1 L11 AND L12

=> d l13 bib ab

L13  ANSWER 1 OF 1  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
AN   1999-634077 [54]   WPIDS
DNC  C1999-185287
TI   Modification and isolation of protein,
     especially whey or soy proteins, for augmenting the
     processing value of whey.
DC   D13
IN   SAVOLAINEN, J
PA   (SAVO-I) SAVOLAINEN J
CYC  21
PI   WO 9955170      A1 19991104 (199954)* EN   25
        RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
         W: AU NZ US
     FI 9800945      A  19991030 (200005)
     AU 9937123      A  19991116 (200015)
     EP 1076489      A1 20010221 (200111)  EN
         R: AT DE DK ES FR GB IE IT NL SE
     FI 107116       B1 20010615 (200145)
     AU 749685       B  20020704 (200255)
     NZ 507646       A  20031128 (200382)
ADT  WO 9955170 A1 WO 1999-FI347 19990428; FI 9800945 A FI 1998-945 19980429;
     AU 9937123 A AU 1999-37123 19990428; EP 1076489 A1 EP 1999-919299
     19990428, WO 1999-FI347 19990428; FI 107116 B1 FI 1998-945 19980429; AU
     749685 B AU 1999-37123 19990428; NZ 507646 A NZ 1999-507646 19990428, WO
     1999-FI347 19990428
FDT  AU 9937123 A Based on WO 9955170; EP 1076489 A1 Based on WO 9955170; FI
     107116 B1 Previous Publ. FI 9800945; AU 749685 B Previous Publ. AU
     9937123, Based on WO 9955170; NZ 507646 A Based on WO 9955170
PRAI FI 1998-945          19980429
AB   WO   9955170 A UPAB: 19991221
     NOVELTY - A protein such as whey or soy (or
     their concentrate) is reacted with a reagent which forms
     sulfite ions  to sulfonate the protein
     without an oxidizing agent. The
     sulfonated protein is precipitated at an acid
     pH. The sulfonated protein or the precipitated
     and/or soluble sulfonated protein is recovered and
     optionally processed.
          USE - Processing (whey) proteins for human consumption and
     functional food products.
          ADVANTAGE - Oxidation in order to change the conformation of the
     protein molecules is unnecessary as the sulfitolysis creates
     sufficient cleavage of disulfide bonds. Omission of oxidation simplifies
     and speeds up the process thereby rendering it more economically
     profitable. The processing value of whey is augmented and the
     profitability of cheese production is increased.
     Dwg.0/0


=> s l7 or l8 or l11 and (l12)
L14         29 L7 OR L8 OR L11 AND (L12)
```

=> s l14 and l10
L15 7 L14 AND L10

=> d l15 1-7 bib ab

L15 ANSWER 1 OF 7 USPATFULL on STN
AN 2004:127423 USPATFULL
TI Pharmaceutical compositions and treatment methods - 4
IN Ahlem, Clarence Nathaniel, San Diego, CA, UNITED STATES
Frincke, James Martin, San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell Neil, Oak Hills, CA, UNITED STATES
PI US 2004097406 A1 20040520
AI US 2003-607035 A1 20030625 (10)
RLI Division of Ser. No. US 2000-535675, filed on 23 Mar 2000, GRANTED, Pat. No. US 6667299 Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 2000-190140P 20000316 (60)
US 1999-164048P 19991108 (60)
US 1999-140028P 19990616 (60)
US 1999-126056P 19991019 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 9339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L15 ANSWER 2 OF 7 USPATFULL on STN
AN 2004:57966 USPATFULL
TI Pharmaceutical compositions and treatment methods
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Heggie, William, Cabanas, PORTUGAL
Carvalho, Luis D., Paio Pires, PORTUGAL
PI US 2004043973 A1 20040304
AI US 2002-319356 A1 20021213 (10)
RLI Continuation of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING
PRAI US 2000-190140P 20000316 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 53
ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)
LN.CNT 9007
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L15 ANSWER 3 OF 7 USPATFULL on STN
AN 2003:332378 USPATFULL
TI Pharmaceutical compositions and treatment methods
IN Ahlem, Clarence Nathaniel, San Diego, CA, United States
de Carvalho, Luis Daniel dos Anjos, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
PA Hollis-Eden Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6667299 B1 20031223
AI US 2000-535675 20000323 (9)
PRAI US 2000-190140P 20000316 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Badio, Barbara P.
LREP Muenchau, Daryl D.
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 8994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising, 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to **make** improved pharmaceutical **formulations.** The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to **make** and use these immunomodulatory compositions and **formulations.**

L15 ANSWER 4 OF 7 USPATFULL on STN
AN 2003:319282 USPATFULL
TI Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2003225031 A1 20031204
AI US 2003-439108 A1 20030515 (10)
PRAI US 2002-382122P 20020521 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)
LN.CNT 2144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compositions of the present invention provide therapeutic **concentrations** of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

L15 ANSWER 5 OF 7 USPATFULL on STN
AN 2003:120747 USPATFULL
TI Blood cell deficiency treatment method
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Reading, Christopher, San Diego, CA, UNITED STATES
Frincke, James, San Diego, CA, UNITED STATES
Stickney, Dwight, Granite Bay, CA, UNITED STATES
Lardy, Henry A., Madison, WI, UNITED STATES
Marwah, Padma, Middleton, WI, UNITED STATES
Marwah, Ashok, Middleton, WI, UNITED STATES
Prendergast, Patrick T., Straffan, IRELAND
PI US 2003083231 A1 20030501
AI US 2002-87929 A1 20020301 (10)
RLI Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2001-820483, filed on 29 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED
PRAI US 1999-161453P 19991025 (60)
US 2001-272624P 20010301 (60)
US 2001-323016P 20010911 (60)
US 2001-340045P 20011130 (60)
US 2001-328738P 20011011 (60)
US 2001-338015P 20011108 (60)
US 2001-343523P 20011220 (60)
US 1999-126056P 19991019 (60)
US 1999-124087P 19990311 (60)
US 1998-109923P 19981124 (60)
US 1998-109924P 19981124 (60)
US 1998-110127P 19981127 (60)
US 1998-112206P 19981215 (60)
US 1999-145823P 19990727 (60)
US 1999-137745P 19990603 (60)
US 1999-140028P 19990616 (60)
DT Utility
FS APPLICATION
LREP HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN DIEGO, CA, 92121
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention

include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

L15 ANSWER 6 OF 7 USPATFULL on STN
AN 2003:99213 USPATFULL
TI High capacity methods for separation, purification, **concentration**, immobilization and synthesis of compounds and applications based thereupon
IN Lee, William, Cambridge, MA, UNITED STATES
Saito, Kyoichi, Tokyo, JAPAN
PI US 2003068317 A1 20030410
AI US 2002-126297 A1 20020419 (10)
PRAI US 2001-285146P 20010420 (60)
US 2001-339951P 20011210 (60)
US 2001-339949P 20011210 (60)
US 2002-347547P 20020111 (60)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY AND POPEO, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 2906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions are provided herein comprising a base material having engrafted polymer brushes. The polymer brushes further comprise one or more functional groups immobilized along the surface of the brushes in a plurality of layers, which confer functional properties to the base material compositions. Methods of using these compositions include deoxygenation of a sample solution, hydrolysis of denaturing agents in a sample solution, resolution of racemic mixtures in a sample solution, and purification, and **concentration** of target compounds.

L15 ANSWER 7 OF 7 USPATFULL on STN
AN 2003:86817 USPATFULL
TI Immune modulation method using steroid compounds
IN Ahlem, Clarence N., San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
dos Anjos de Carvalho, Luis Daniel, Paio Pires, PORTUGAL
Heggie, William, Palmela, PORTUGAL
Prendergast, Patrick T., County Kildare, IRELAND
Reading, Christopher L., San Diego, CA, UNITED STATES
Thadikonda, Krupakar Paul, Gaithersburg, MD, UNITED STATES
Vernon, Russell N., Oak Hills, CA, UNITED STATES
PI US 2003060425 A1 20030327
AI US 2001-820483 A1 20010329 (9)
RLI Continuation-in-part of Ser. No. US 1999-449184, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414905, filed on 8 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-449004, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-535675, filed on 23 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1999-449042, filed on 24 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-675470, filed on 28 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-586673, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-586672, filed on 1 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-461026, filed on 15 Dec 1999, ABANDONED
PRAI US 1998-109924P 19981124 (60)
US 1999-140028P 19990616 (60)
US 1998-109923P 19981124 (60)

```
        US 1999-126056P     19991019 (60)
        US 1999-124087P     19990311 (60)
        US 1998-110127P     19981127 (60)
        US 1999-161453P     19991025 (60)
        US 1999-145823P     19990727 (60)
        US 1999-137745P     19990603 (60)
        US 1998-112206P     19981215 (60)
        US 2000-257071P     20001220 (60)
DT      Utility
FS      APPLICATION
LREP    HOLLIS-EDEN PHARMACEUTICALS, INC., 4435 EASTGATE MALL, SUITE 400, SAN
        DIEGO, CA, 92121
CLMN    Number of Claims: 54
ECL     Exemplary Claim: 1
DRWN    6 Drawing Page(s)
LN.CNT 14708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The invention provides compositions comprising formula 1 steroids, e.g.,
        16α-bromo-3 β-hydroxy-5α-androstan-17-one hemihydrate
        and one or more excipients, including compositions that comprise a
        liquid formulation comprising less than about 3% v/v water.
        The compositions are useful to make improved pharmaceutical
        formulations. The invention also provides methods of
        intermittent dosing of steroid compounds such as analogs of
        16α-bromo-3β-hydroxy-5α-androstan-17-one and
        compositions useful in such dosing regimens. The invention further
        provides compositions and methods to inhibit pathogen replication,
        ameliorate symptoms associated with immune dysregulation and to modulate
        immune responses in a subject using the compounds. The invention also
        provides methods to make and use these immunomodulatory
        compositions and formulations.


=> d his

     (FILE 'HOME' ENTERED AT 11:49:47 ON 26 MAY 2004)

     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 11:50:33 ON 26 MAY 2004
L1       141102 S (SULFITE# OR SULPHITE#)
L2        51851 S L1 AND (SODIUM SULFITE OR SODIUM SULPHITE OR NA2SO3 OR SULFUR
L3          421 S L2 AND (PROTEIN(L)SOY OR WHEY)
L4          408 S L3 AND (PREPAR? OR MODIF? OR MAK? OR ISOLAT? OR FORMULAT? OR
L5          368 S L4 AND (PPT# OR PRECIP? OR AGGREGAT? OR CONCENTRAT? OR CENTR
L6          142 S L5 AND (SULFONAT?(W)PROTEIN OR PROTEIN(L)SULFON?)
L7           21 S L6 AND (ACID?(W)PH)
L8           12 S L6 AND (ENZYMAT?(W)HYDROLYSIS)
L9            4 S L7 AND L8
L10           7 S L8 AND (PEPSIN OR TRYPSIN)
L11          28 S L6 AND (WITHOUT(L)OXIDIZING AGENT OR NO OXIDIZ?(W)AGENT#)
L12         414 S SAVOLAINEN, J?/AU
L13           1 S L11 AND L12
L14          29 S L7 OR L8 OR L11 AND (L12)
L15           7 S L14 AND L10

=> s l11 or l14 and (l12)
L16         30 L11 OR L14 AND (L12)

=> s l13 and l16
L17          1 L13 AND L16

=> s l12 and l17
L18          1 L12 AND L17

=> s l18 and 18
```

```
L19           0 L18 AND L8

=> s l18 and (enzymat?(w)hydrolysis)
L20           0 L18 AND (ENZYMAT?(W) HYDROLYSIS)

=> s l16 and (sulfitlysis)
L21           0 L16 AND (SULFITLYSIS)

=> s l16 and (sulfitolysis)
L22           6 L16 AND (SULFITOLYSIS)

=> d l22 1-6 bib ab

L22  ANSWER 1 OF 6  USPATFULL on STN
AN      1998:138493  USPATFULL
TI      Method for isolating whey proteins
IN      Savolainen, Jouko, Kuurinniityntie 26, FIN-02700 Kauniainen,
        Finland
PI      US 5834042              19981110
        WO 9522907  19950831
AI      US 1996-619666          19961114 (8)
        WO 1995-FI91            19950222
                                19961114  PCT 371 date
                                19961114  PCT 102(e) date
PRAI    FI 1994-846         19940223
DT      Utility
FS      Granted
EXNAM   Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Lukton, David
LREP    Loeb & Loeb LLP
CLMN    Number of Claims: 38
ECL     Exemplary Claim: 1
DRWN    No Drawings
LN.CNT 771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The invention relates to a method for isolating proteins from
        whey, wherein the whey or a concentrate
        thereof, a reagent which forms sulfite ions, and an oxidative
        compound are contacted in order to sulfitolyze and oxidize the
        whey protein, the sulfitolyzed and oxidized whey
        protein is precipitated out from the whey or
        concentrate thereof at an acid pH, and the
        precipitated sulfitolyzed and oxidized whey protein is
        recovered from the product mixture, and an after-treatment is
        possibly performed on it. When a food-grade oxidative compound is used
        as the oxidant and a temperature within the range 25°-55°
        C. is used, the oxidative compound can be caused to react directly with
        the sulfitolyzed whey protein, and thus the disadvantages
        associated with the use of a catalyst are eliminated.

L22  ANSWER 2 OF 6  USPATFULL on STN
AN      95:20436  USPATFULL
TI      Cleaning composition containing a type II endoglycosidase
IN      Carpenter, Richard S., Cincinnati, OH, United States
        Goldstein, Irwin J., Ann Arbor, MI, United States
        Lad, Pushkaraj J., San Mateo, CA, United States
        Wolff, Ann M., Cincinnati, OH, United States
PA      The Procter & Gamble Company, Cincinnati, OH, United States (U.S.
        corporation)
        Genencor International, Inc., Rochester, NY, United States (U.S.
        corporation)
PI      US 5395541              19950307
AI      US 1993-98083           19930726 (8)
RLI     Division of Ser. No. US 1989-428361, filed on 27 Oct 1989, now patented,
        Pat. No. US 5238843
DT      Utility
```

FS Granted
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Meller, Mike
LREP Horn, Margaret A.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cleaning composition is disclosed. The composition contains a first enzyme where the enzyme can be Endo-D, Endo-H, Endo-L, Endo-C, Endo-CII, Endo-F-Gal type, Endo-F and PNGaseF and a second enzyme where the enzyme can be a protease, lipase, nuclease, glycosidase, an enzyme different from the first enzyme, and any combination of these. The composition also contains a detergent surfactant and a builder. The composition can be used in a method for cleaning a surface on which is bound a glycoside-containing substance. The substance can be blood or components thereof, fecal matter or components thereof or microorganisms. The surface can be fabric, biological tissue, tooth enamel, contact lens, glass, ceramic, metal, metal alloy, plastic, plant, fruit and vegetable.

L22 ANSWER 3 OF 6 USPATFULL on STN
AN 94:90961 USPATFULL
TI Antimicrobial composition containing Type II endoglycosidase and antimicrobial agent
IN Carpenter, Richard S., Cincinnati, OH, United States
Lad, Pushkaraj J., San Mateo, CA, United States
Wolff, Ann M., Cincinnati, OH, United States
PA Genencor International, Inc., So. San Francisco, CA, United States (U.S. corporation)
The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5356803 19941018
AI US 1992-869356 19920330 (7)
DCD 20100824
RLI Continuation of Ser. No. US 1989-428362, filed on 27 Oct 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Meller, Michael V.
LREP Horn, Margaret A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An antimicrobial composition consisting essentially of from about 1 ppm to about 1200 ppm of a Type II endoglycosidase and from about 0.5 ppm to about 1200 ppm of an antimicrobial agent is disclosed. The preferred Type II endoglycosidases to be used in the invention are Endo-D, Endo-H, Endo-F and PNGaseF. The preferred antimicrobial agents are bactericides, fungicides and algicides. The composition can be used in the form of personal care or household cleaning **products** such as liquid soap, hard surface cleaner, laundry detergent, anti-acne medication, deodorant, shampoo, face cream, mouthwash, dentifrice and denture cleaner.

L22 ANSWER 4 OF 6 USPATFULL on STN
AN 93:91558 USPATFULL
TI Method of removing microorganisms from surfaces with Type II endoglycosidase
IN Carpenter, Richard S., Cincinnati, OH, United States
Lad, Pushkaraj J., San Mateo, CA, United States
Wolff, Ann M., Cincinnati, OH, United States
PA Genencor International, Inc., So. San Francisco, CA, United States (U.S. corporation)

P&G, Cincinnati, OH, United States (U.S. corporation)
PI US 5258304 19931102
AI US 1989-428248 19891027 (7)
DCD 20100824
DT Utility
FS Granted
EXNAM Primary Examiner: Naff, David M.
LREP Horn, Margaret A.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Microorganisms are removed from the surface of materials such as fabrics or contact lenses by treatment with a Type II endoglycosidase. The Type II endoglycosidase may be used alone or in combination with other enzymes, detergents, surfactants and/or disulfide cleaving reagents to facilitate removal of the microorganisms. The Type II endoglycosidase may be an Endo-β-N-acetylglucosaminidase, Endo-α-N-acetylgalactosaminidase or Endo-β-N-galactosidase.

L22 ANSWER 5 OF 6 USPATFULL on STN
AN 93:69772 USPATFULL
TI Method for cleaning a surface on which is bound a glycoside-containing substance
IN Carpenter, Richard S., Cincinnati, OH, United States
Goldstein, Irwin J., Ann Arbor, MI, United States
Lad, Pushkaraj J., San Mateo, CA, United States
Wolff, Ann M., Cincinnati, OH, United States
PA Genencor International, Inc., So. San Francisco, CA, United States (U.S. corporation)
The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5238843 19930824
AI US 1989-428361 19891027 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Naff, David M.; Assistant Examiner: Meller, Michael V.
LREP Horn, Margaret A.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for cleaning a surface on which is bound a glycoside-containing substance. The substance can be blood or components thereof, fecal matter or components thereof or microorganisms. The surface can be fabric, biological tissue, tooth enamel, contact lens, glass, ceramic, metal, metal alloy, plastic, plant, fruit and vegetable. A Type II endoglycosidase is used to carry out the method.

L22 ANSWER 6 OF 6 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1999-634077 [54] WPIDS
DNC C1999-185287
TI **Modification** and **isolation** of **protein**, especially **whey** or **soy** proteins, for augmenting the processing value of **whey.**
DC D13
IN **SAVOLAINEN, J**
PA (SAVO-I) SAVOLAINEN J
CYC 21
PI WO 9955170 A1 19991104 (199954)* EN 25
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU NZ US
FI 9800945 A 19991030 (200005)

AU 9937123 A 19991116 (200015)
EP 1076489 A1 20010221 (200111) EN
R: AT DE DK ES FR GB IE IT NL SE
FI 107116 B1 20010615 (200145)
AU 749685 B 20020704 (200255)
NZ 507646 A 20031128 (200382)

ADT WO 9955170 A1 WO 1999-FI347 19990428; FI 9800945 A FI 1998-945 19980429; AU 9937123 A AU 1999-37123 19990428; EP 1076489 A1 EP 1999-919299 19990428, WO 1999-FI347 19990428; FI 107116 B1 FI 1998-945 19980429; AU 749685 B AU 1999-37123 19990428; NZ 507646 A NZ 1999-507646 19990428, WO 1999-FI347 19990428

FDT AU 9937123 A Based on WO 9955170; EP 1076489 A1 Based on WO 9955170; FI 107116 B1 Previous Publ. FI 9800945; AU 749685 B Previous Publ. AU 9937123, Based on WO 9955170; NZ 507646 A Based on WO 9955170

PRAI FI 1998-945 19980429

AB WO 9955170 A UPAB: 19991221

NOVELTY - A **protein** such as **whey** or **soy** (or their **concentrate**) is reacted with a reagent which forms **sulfite** ions to **sulfonate** the **protein** **without** an **oxidizing agent.** The **sulfonated protein** is **precipitated** at an **acid pH.** The **sulfonated protein** or the **precipitated** and/or soluble **sulfonated** **protein** is recovered and optionally processed.

USE - Processing (**whey**) proteins for human consumption and functional food **products.**

ADVANTAGE - Oxidation in order to change the conformation of the **protein** molecules is unnecessary as the **sulfitolysis** creates sufficient cleavage of disulfide bonds. Omission of oxidation simplifies and speeds up the process thereby rendering it more economically profitable. The processing value of **whey** is augmented and the profitability of cheese **production** is increased.

Dwg.0/0

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 12:21:43 ON 26 MAY 2004